Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
4(67%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_1
1
17%
Ph early_phase_1
1
17%
Ph phase_2
3
50%

Phase Distribution

2

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Completed(2)

Detailed Status

Recruiting3
Completed2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
4
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (20.0%)
Phase 11 (20.0%)
Phase 23 (60.0%)

Trials by Status

active_not_recruiting117%
recruiting350%
completed233%

Recent Activity

4 active trials
Showing 5 of 6
recruitingphase_2

An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain Tumors

NCT06667726
active_not_recruitingphase_2

Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study

NCT05781321
recruitingearly_phase_1

Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease

NCT07025226
completed

An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas

NCT05560009
completedphase_2

18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy

NCT03778294
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06667726Phase 2

An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain Tumors

Recruiting
NCT05781321Phase 2

Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study

Active Not Recruiting
NCT07025226Early Phase 1

Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease

Recruiting
NCT05560009

An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas

Completed
NCT03778294Phase 2

18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy

Completed
NCT02021604Phase 1

Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma

Recruiting

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6